Q-omics provides the consensus-scored PDGFC profile across patient tissues and cancer cell-line models. PDGFC expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PDGFC is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PDGFC RNA expression shows 19,235 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where PDGFC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDGFC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDGFC survival associations across molecular data types. PDGFC RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDGFC RNA expression–survival associations across cancer types. High PDGFC expression shows unfavorable associations in STAD, BLCA, MESO and LUSC, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for PDGFC RNA expression.
This table summarizes PDGFC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PDGFC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDGFC shows lower tumor expression in UCEC and BRCA and higher tumor expression in HNSC, LUAD, THCA and CHOL. The HNSC box plot shows higher PDGFC RNA expression in tumor versus normal tissue (log2 FC = +1.232, t-test p < 0.001).
This table shows molecular features associated with PDGFC in patient tissues and cancer cell lines. In patient samples, PDGFC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDGFC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
